May 20, 2012

Three Late-Stage Leukemia Company Previews for ASCO

blood_slide

Three companies with late-stage development programs for the treatment of AML are expected to provide updates at the 2011 ASCO annual meeting.

Investment Opportunities with Five Frontline Therapies for AML

473462-small

Acute myelogenous leukemia [AML] is a fast-growing cancer of the blood and bone marrow.  Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet.  In AML, abnormal blasts produce white blood cells that do not function [...]

Gut Check Time for GVHD Companies: BMT Tandem Meetings Review

1764831-smallslide

The 2010 BMT Tandem Meetings were held in Orlando, Florida this past week [February 24-28, 2010].  Considered the premier event for hematopoietic cell transplantation [HCT] and cellular therapy, the annual event attracts more than 2,500 clinicians, transplant nurses, clinical research professionals, data managers, pharmacists, center administrators and mid-level practitioners. With more than 200 abstracts being [...]